We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App





GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test

By LabMedica International staff writers
Posted on 02 Dec 2020
Print article
Image: GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test (Photo courtesy of TCA/GENETWORx Labs)
Image: GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test (Photo courtesy of TCA/GENETWORx Labs)
TCA/GENETWORx Labs (Glen Allen, VA, USA) has unveiled a new breakthrough diagnostic Flu A-B/COVID-19/RSV combination test that provides patients with early detection of all three separate respiratory viruses with just one test sample.

With people inside homes, businesses, and schools during the cold weather months where there is less ventilation, the COVID-19 virus coupled with influenza and RSV (Respiratory Syncytial Virus) pose a formidable and unprecedented infectious disease threat, particularly since these viruses share similar symptoms. To help battle this triple threat, the new TCA/GENETWORx Combo PCR test provides patients the ability to detect strands of influenza A and B, RSV, and COVID-19 all from a single sample. The molecular diagnostic PCR test detects two types of influenza viruses - influenza A and B - and differentiates them from RSV, and SARS-CoV-2, the virus that causes COVID-19. The Flu A-B/COVID Combo Test provided by GENETWORx has a 98% accuracy rate for influenza, 99% for COVID-19, and 96% for RSV.

The capability to test for influenza A/B, RSV, and COVID-19 from a single mid-turbinate or nasopharyngeal swab sample means less discomfort for patients when compared with collecting a separate sample for each test. Testing a single sample for several pathogens uses fewer resources and takes less time when compared with running several individual tests on multiple samples to detect different pathogens.

An approval date for a COVID-19 vaccine is still yet to be determined and the flu vaccine is dependent on which strain of influenza is circulating each year. There is currently no vaccine for RSV. Even with the correct strain, the flu vaccine is not 100% reliable. With all the unknowns and risks associated with this upcoming flu and RSV season, the new TCA/GENETWORx test is an important advancement in diagnostic medicine during the pandemic.

"With this new combination test, healthcare providers can provide an accurate diagnosis to patients and treat them with the appropriate measures. Patients then can observe appropriate quarantine measures to stop the spread," said William Miller, CEO of GENETWORx Labs. "Having a combination test that detects three different viruses is a healthcare breakthrough for both providers and patients and will save lives. The Combo test is also easier on patients since only one sample is needed for three answers."

Related Links:
TCA/GENETWORx Labs


Print article

Channels

Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.